RET and neoplasm: As expected in this model, cabozantinib slowed growth but did not lead to any tumor shrinkage at a dosage that has been shown to completely inhibit growth of RET fusion-driven xenograft tumors (30 mg per kg QD)41, while vandetanib and vepafestinib treatment caused substantial tumor regression (Fig. 5c, middle and right).